Evidence map›Paper›PMID 40999970›Full record

ArticleOncology reports2025

Relationship between amino acid transporter activity and radioactive iodine therapy efficacy in differentiated thyroid cancer.

Akihito Kotani, Yota Tatara, Riki Sakamoto, Andrzej Wojcik, Yasushi Mariya, Satoru Monzen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akihito KotaniDepartment of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan.
Yota TataraDepartment of Stress Response Science, Biomedical Research Center, Graduate School of Medicine, Hirosaki University, Hirosaki, Aomori 036‑8562, Japan.
Riki SakamotoDepartment of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan.
Andrzej WojcikCentre for Radiation Protection Research, Stockholm University, SE‑10691 Stockholm, Sweden.
Yasushi MariyaCenter for Cancer Treatment and Examination, Aomori Rosai Hospital, Hachinohe, Aomori 031‑8551, Japan.
Satoru MonzenDepartment of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer is the most common malignant endocrine tumor. Differentiated thyroid cancer (DTC) accounts for 95% of thyroid cancer cases. The primary treatment for intermediate‑ and high‑risk DTC is total thyroidectomy. Postoperatively, serum thyroglobulin (Tg) and anti‑Tg antibody (Tg/Ab) levels are monitored to detect residual, recurrent or metastatic disease. Radioactive iodine (

Indexed as

Amino Acid Transport SystemsIodine RadioisotopesThyroid NeoplasmsAdultAgedAutoantibodiesBiomarkers, TumorCell Line, TumorFemaleHumansMaleMiddle AgedThyroglobulinThyroidectomyThyrotropinTreatment OutcomeAmino Acid Transport Systemsanti-thyroglobulinAutoantibodiesBiomarkers, TumorIodine-131Iodine RadioisotopesTG protein, humanThyroglobulinThyrotropinbranched‑chain amino aciddifferentiated thyroid cancerL‑type amino acid transporter 1radioisotope therapy

Identifiers

PMID40999970
PMCPMC12489427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.